Novintum: bugging cancer

Why Novintum is targeting mitochondria with antibiotics to treat cancer

Springing off the endosymbiotic theory, which holds that mitochondria evolved from primitive bacteria, Novintum Bioscience Ltd. is targeting mitochondrial metabolism with antibiotics to treat relapsed or treatment-resistant cancers.

CEO Tim Sparey said Novintum’s strategy arose from the company’s observation that relapsed or treatment-resistant cancer cells produce more ATP and undergo more frequent mitochondrial

Read the full 521 word article

How to gain access

Continue reading with a
two-week free trial.